Telomir Pharmaceuticals (TELO) Non-Current Assets (2023)
Telomir Pharmaceuticals (TELO) posted Non-Current Assets of $4.3 million for Q4 2023.
Telomir Pharmaceuticals (TELO) Non-Current Assets (2023) Analysis & Trends
Telomir Pharmaceuticals has reported Non-Current Assets for 1 years, with the latest figure at $4.3 million in Q4 2023.
- Quarterly Non-Current Assets changed N/A year-over-year to $4.3 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $4.3 million (changed N/A YoY) and the FY2023 annual result came in at $4.3 million, changed N/A from the prior year.
- Non-Current Assets steadied at $4.3 million in Q4 2023 per TELO's latest filing.
- Over five years, Non-Current Assets peaked at $4.3 million in Q4 2023 and troughed at $4.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.34 Mn |